Skip to main content
. 2010 Jan 13;115(19):3869–3878. doi: 10.1182/blood-2009-10-248997

Figure 1.

Figure 1

Treatment schema. Patients who relapsed after MHC-matched allogeneic HCT and elected to receive chemotherapy and T-cell therapy first underwent withdrawal of immunosuppression, followed sequentially by appropriate salvage chemotherapy, adoptive T-cell therapy with CD8+ mHAg-specific CTL clones, and a 14-day course of low-dose IL-2.